Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr2.29
kr0.25(10.92%)
At close: 4:00 PM EDT
kr2.29
kr0.25(10.92%)
Day’s Range― - ―
52-Week Rangekr2.24 - kr4.07
Previous CloseN/A
Volume40.71K
Average Volume (3M)133.41K
Market Cap
kr156.76M
Enterprise Valuekr121.90M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA clear therapeutic focus on CNS and male sexual health creates durable strategic clarity: it concentrates R&D efforts, enables targeted regulatory strategies, and makes the program more partnerable. Over 2-6 months this preserves optionality for licensing or co-development.
Low Leverage And Positive EquityVery low debt reduces insolvency and interest burden risk, while positive equity provides a baseline buffer and financing flexibility. This structural balance-sheet strength supports continued R&D and negotiation leverage with partners or investors over the medium term.
Improving Free Cash Flow TrendAn improving FCF trend and FCF that is materially less negative than net income (about 0.68x) indicate better cash efficiency and capital discipline. This structural improvement eases funding pressure and enhances the company's ability to extend runway or attract partners.
Bears Say
Pre-revenue Status With Widening LossesBeing pre-revenue with materially wider losses means the firm cannot self-fund operations and remains highly dependent on external capital. Over the next several months this elevates dilution risk, limits strategic optionality, and reduces visibility into sustainable profitability.
Sustained Negative Operating Cash FlowPersistent operating cash outflows are a structural constraint: they force repeated fundraising or partner deals, can delay programs if financing terms worsen, and increase governance scrutiny. This ongoing burn is a core durability risk for development timelines.
Declining Equity And Negative ReturnsDeclining book equity and negative ROE signal shareholder value erosion from losses. Structurally this reduces capital cushions against shocks, raises the likelihood of dilutive raises, and pressures management to prioritize financing over long-term value creation.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.24 and its highest was kr4.07 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr156.76M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 25 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.